Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1,  a self-developed and ...

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its Year-end report for the period January - December 2024 is now available on the company's website: "The ...

STOCKHOLM, SWEDEN / ACCESS Newswire / February 27, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma ... ACD137 are at least on par with the antibody Tanuzemab, while also exhibiting ...

These 2 oval masses are in the back of the throat ... But the goal of protecting the body from infection remains the same. The B cells make specific antibodies to fight germs. The T cells kill the ...

Free route airspace (FRA) is a specified airspace within which users may freely plan a route between a defined entry point and a defined exit point, with the possibility to route via intermediate ...

What makes your blood different from someone else’s is your unique combination of protein molecules, called antigens and antibodies. Antigens live on the surface of your red blood cells.

Share on Pinterest Scientists have found that an antibody treatment prevented a decline in muscle mass and bone density after using GLP-1 drugs. Rob and Julia Campbell/Stocksy Aging and limited ...

Premium Quality Power IPO Day 2 Highlights: The subscription period for the Quality Power IPO is scheduled from Friday, February 14, to Tuesday, February 18. Quality Power IPO Day 2 Highlights ...

Credit: kirisa99 via Getty Images. US-based startup Bambusa Therapeutics has secured $90m in Series A financing to advance its pipeline of bispecific antibodies for immunological and inflammatory ...

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates ...

Bambusa Therapeutics raised around $90 million in a series A round Friday to drive the development of bispecific antibodies for immunological and inflammatory disorders ... including Eli Lilly’s $3.2 ...